Therefore, inhibition of DOT1L by SYC-522 treatment shows that reducing DOT1L methyltransferase activity and its downstream targets MEIS1 and HOXA9, can promote differentiation and might represent a valuable approach for treating MLL-rearranged leukemia. This evidence concerns the gene KMT2A and leukemia.